| Target Price | HK$32.74 |
| Price | HK$39.34 |
| Deviation |
16.77%
register free of charge
|
| Number of Estimates | 9 |
|
9 Analysts have issued a price target Genscript Biotech Corp 2027 .
The average Genscript Biotech Corp target price is HK$32.74.
This is
16.77%
register free of charge
HK$40.47
2.86%
register free of charge
HK$16.06
59.18%
register free of charge
|
|
| A rating was issued by 15 analysts: 14 Analysts recommend Genscript Biotech Corp to buy, 1 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Genscript Biotech Corp stock has an average upside potential 2027 of
16.77%
register free of charge
|
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Revenue Billion HK$ | 7.53 | 6.96 |
| 61.40% | 7.59% | |
| EBITDA Margin | 33.31% | 16.99% |
| 737.35% | 48.99% | |
| Net Margin | -55.53% | 7.19% |
| 111.15% | 112.95% |
11 Analysts have issued a sales forecast Genscript Biotech Corp 2026 . The average Genscript Biotech Corp sales estimate is
This results in the following potential growth metrics:
11 Genscript Biotech Corp Analysts have issued a net profit forecast 2026. The average Genscript Biotech Corp net profit estimate is
This results in the following potential growth metrics and future Net Margins:
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Earnings Per Share HK$ | -1.93 | 0.23 |
| 117.71% | 111.92% | |
| P/E | 172.08 | |
| EV/Sales | 11.61 |
11 Analysts have issued a Genscript Biotech Corp forecast for earnings per share. The average Genscript Biotech Corp EPS is
This results in the following potential growth metrics and future valuations:
Genscript Biotech Corp...
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


